APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live and Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live and Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025192 pages

Choose your research edition.

Industry ResearchLive and Attenuated Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Live and Attenuated Vaccine Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Live and Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live and Attenuated Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Live and Attenuated Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Live and Attenuated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live and Attenuated Vaccine include Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Inc, GlaxoSmithKline, Serum Institute, MedImmune, LLC, Emergent BioSolutions, Inc. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live and Attenuated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live and Attenuated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live and Attenuated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live and Attenuated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live and Attenuated Vaccine Segment by Company

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer, Inc

GlaxoSmithKline

Serum Institute

MedImmune, LLC

Emergent BioSolutions, Inc.

CSL Limited

Astellas Pharma Inc

Live and Attenuated Vaccine Segment by Type

Pediatric Vaccine

Adult Vaccines

Live and Attenuated Vaccine Segment by Application

Clinics

Diagnostic Centers

Hospitals

Research Institute

Others

Live and Attenuated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live and Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live and Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live and Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live and Attenuated Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Live and Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Live and Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Live and Attenuated Vaccine Industry Trends Table 2. Live and Attenuated Vaccine Industry Drivers Table 3. Live and Attenuated Vaccine Industry Opportunities and Challenges Table 4. Live and Attenuated Vaccine Industry Restraints Table 5. Global Live and Attenuated Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Live and Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Live and Attenuated Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Live and Attenuated Vaccine Sales Market Share by Manufacturers Table 9. Global Live and Attenuated Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Live and Attenuated Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Live and Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Live and Attenuated Vaccine Manufacturers, Product Type & Application Table 13. Global Live and Attenuated Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Live and Attenuated Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pediatric Vaccine Table 17. Major Manufacturers of Adult Vaccines Table 18. Global Live and Attenuated Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 20. Global Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 21. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Live and Attenuated Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Live and Attenuated Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Live and Attenuated Vaccine Revenue by Type (2021-2026) & (k units) Table 25. Global Live and Attenuated Vaccine Revenue by Type (2027-2032) & (k units) Table 26. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Live and Attenuated Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Clinics Table 29. Major Manufacturers of Diagnostic Centers Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Research Institute Table 32. Major Manufacturers of Others Table 33. Global Live and Attenuated Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 35. Global Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 36. Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2026) Table 37. Global Live and Attenuated Vaccine Sales Market Share by Application (2027-2032) Table 38. Global Live and Attenuated Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Live and Attenuated Vaccine Revenue by Application (2021-2026) & (k units) Table 40. Global Live and Attenuated Vaccine Revenue by Application (2027-2032) & (k units) Table 41. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2026) Table 42. Global Live and Attenuated Vaccine Revenue Market Share by Application (2027-2032) Table 43. Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Live and Attenuated Vaccine Sales by Region (2021-2026) & (k units) Table 45. Global Live and Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Live and Attenuated Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Live and Attenuated Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 50. North America Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 51. Europe Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 53. Europe Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 60. Global Live and Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Live and Attenuated Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Live and Attenuated Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Live and Attenuated Vaccine Revenue Market Share by Region (2021-2026) Table 64. Global Live and Attenuated Vaccine Revenue Market Share by Region (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sanofi Live and Attenuated Vaccine Product Portfolio Table 69. Sanofi Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Live and Attenuated Vaccine Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Merck & Co. Company Information Table 76. Merck & Co. Business Overview Table 77. Merck & Co. Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck & Co. Live and Attenuated Vaccine Product Portfolio Table 79. Merck & Co. Recent Development Table 80. Pfizer, Inc Company Information Table 81. Pfizer, Inc Business Overview Table 82. Pfizer, Inc Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer, Inc Live and Attenuated Vaccine Product Portfolio Table 84. Pfizer, Inc Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. Serum Institute Company Information Table 91. Serum Institute Business Overview Table 92. Serum Institute Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Serum Institute Live and Attenuated Vaccine Product Portfolio Table 94. Serum Institute Recent Development Table 95. MedImmune, LLC Company Information Table 96. MedImmune, LLC Business Overview Table 97. MedImmune, LLC Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. MedImmune, LLC Live and Attenuated Vaccine Product Portfolio Table 99. MedImmune, LLC Recent Development Table 100. Emergent BioSolutions, Inc. Company Information Table 101. Emergent BioSolutions, Inc. Business Overview Table 102. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio Table 104. Emergent BioSolutions, Inc. Recent Development Table 105. CSL Limited Company Information Table 106. CSL Limited Business Overview Table 107. CSL Limited Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. CSL Limited Live and Attenuated Vaccine Product Portfolio Table 109. CSL Limited Recent Development Table 110. Astellas Pharma Inc Company Information Table 111. Astellas Pharma Inc Business Overview Table 112. Astellas Pharma Inc Live and Attenuated Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio Table 114. Astellas Pharma Inc Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Live and Attenuated Vaccine Distributors List Table 118. Live and Attenuated Vaccine Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Live and Attenuated Vaccine Product Image Figure 2. Global Live and Attenuated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live and Attenuated Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Live and Attenuated Vaccine Sales (2021-2032) & (k units) Figure 5. Global Live and Attenuated Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Live and Attenuated Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pediatric Vaccine Image Figure 9. Adult Vaccines Image Figure 10. Global Live and Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Live and Attenuated Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Live and Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Live and Attenuated Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Clinics Image Figure 17. Diagnostic Centers Image Figure 18. Hospitals Image Figure 19. Research Institute Image Figure 20. Others Image Figure 21. Global Live and Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Live and Attenuated Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2032) Figure 24. Global Live and Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Live and Attenuated Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2032) Figure 27. North America Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Live and Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 29. U.S. Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Live and Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 34. Germany Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Live and Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 41. China Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Live and Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 49. Brazil Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Live and Attenuated Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Live and Attenuated Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Live and Attenuated Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. North America Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Europe Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Live and Attenuated Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Live and Attenuated Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Vaccine
  • Adult Vaccines
Applications
  • Clinics
  • Diagnostic Centers
  • Hospitals
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer, Inc
  • GlaxoSmithKline
  • Serum Institute
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live and Attenuated Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live and Attenuated Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Live and Attenuated Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Live and Attenuated Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Live and Attenuated Vaccine Market Dynamics
  1. 2.1 Live and Attenuated Vaccine Industry Trends
  2. 2.2 Live and Attenuated Vaccine Industry Drivers
  3. 2.3 Live and Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Live and Attenuated Vaccine Industry Restraints
3 Live and Attenuated Vaccine Market by Manufacturers
  1. 3.1 Global Live and Attenuated Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Live and Attenuated Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Live and Attenuated Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Live and Attenuated Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live and Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Live and Attenuated Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Live and Attenuated Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live and Attenuated Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live and Attenuated Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live and Attenuated Vaccine Tier 1, Tier 2, and Tier 3
4 Live and Attenuated Vaccine Market by Type
  1. 4.1 Live and Attenuated Vaccine Type Introduction
  2. 4.1.1 Pediatric Vaccine
  3. 4.1.2 Adult Vaccines
  4. 4.2 Global Live and Attenuated Vaccine Sales by Type
  5. 4.2.1 Global Live and Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live and Attenuated Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Live and Attenuated Vaccine Revenue by Type
  9. 4.3.1 Global Live and Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live and Attenuated Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2032)
5 Live and Attenuated Vaccine Market by Application
  1. 5.1 Live and Attenuated Vaccine Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Hospitals
  5. 5.1.4 Research Institute
  6. 5.1.5 Others
  7. 5.2 Global Live and Attenuated Vaccine Sales by Application
  8. 5.2.1 Global Live and Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Live and Attenuated Vaccine Sales by Application (2021-2032)
  10. 5.2.3 Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2032)
  11. 5.3 Global Live and Attenuated Vaccine Revenue by Application
  12. 5.3.1 Global Live and Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Live and Attenuated Vaccine Revenue by Application (2021-2032)
  14. 5.3.3 Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2032)
6 Global Live and Attenuated Vaccine Sales by Region
  1. 6.1 Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live and Attenuated Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live and Attenuated Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Live and Attenuated Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Live and Attenuated Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Live and Attenuated Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Live and Attenuated Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Live and Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Live and Attenuated Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Live and Attenuated Vaccine Revenue by Region
  1. 7.1 Global Live and Attenuated Vaccine Revenue by Region
  2. 7.1.1 Global Live and Attenuated Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Live and Attenuated Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Live and Attenuated Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Live and Attenuated Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Live and Attenuated Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Live and Attenuated Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Live and Attenuated Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Live and Attenuated Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Live and Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Live and Attenuated Vaccine Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Pfizer, Inc
  20. 8.4.1 Pfizer, Inc Company Information
  21. 8.4.2 Pfizer, Inc Business Overview
  22. 8.4.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
  24. 8.4.5 Pfizer, Inc Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Serum Institute
  32. 8.6.1 Serum Institute Company Information
  33. 8.6.2 Serum Institute Business Overview
  34. 8.6.3 Serum Institute Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
  36. 8.6.5 Serum Institute Recent Developments
  37. 8.7 MedImmune, LLC
  38. 8.7.1 MedImmune, LLC Company Information
  39. 8.7.2 MedImmune, LLC Business Overview
  40. 8.7.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
  42. 8.7.5 MedImmune, LLC Recent Developments
  43. 8.8 Emergent BioSolutions, Inc.
  44. 8.8.1 Emergent BioSolutions, Inc. Company Information
  45. 8.8.2 Emergent BioSolutions, Inc. Business Overview
  46. 8.8.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
  48. 8.8.5 Emergent BioSolutions, Inc. Recent Developments
  49. 8.9 CSL Limited
  50. 8.9.1 CSL Limited Company Information
  51. 8.9.2 CSL Limited Business Overview
  52. 8.9.3 CSL Limited Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
  54. 8.9.5 CSL Limited Recent Developments
  55. 8.10 Astellas Pharma Inc
  56. 8.10.1 Astellas Pharma Inc Company Information
  57. 8.10.2 Astellas Pharma Inc Business Overview
  58. 8.10.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
  60. 8.10.5 Astellas Pharma Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live and Attenuated Vaccine Value Chain Analysis
  2. 9.1.1 Live and Attenuated Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live and Attenuated Vaccine Production Mode & Process
  6. 9.2 Live and Attenuated Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live and Attenuated Vaccine Distributors
  9. 9.2.3 Live and Attenuated Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst